Cytokinetics Goes Ahead with Tirasemtiv Trial and Increases Enrollment

Cytokinetics, Inc. is currently conducting a 500 person Phase II clinical trial of their skeletal muscle activator tirasemtiv for the treatment of ALS. Unfortunately, the Phase II trial had a recent setback due to a contractor’s computer programming error that resulted in 58 patients receiving placebo instead of the study drug by mistake. To compensate for this error, Cytokinetics recently announced that they are increasing the size of their Phase II trial to 680 patients, which is good news for patients and researchers. The trial is expected to conclude in late 2013, and the results from the trial will be announced sometime in early 2014. Increasing the trial by 180 patients will cost an estimated additional $5 million. Read more about the changes to the Phase II trial by clicking the link below.

Cytokinetics, Inc. is currently conducting a 500 person Phase II clinical trial of their skeletal muscle activator tirasemtiv for the treatment of ALS. Unfortunately, the Phase II trial had a recent setback due to a contractor’s computer programming error that resulted in 58 patients receiving placebo instead of the study drug by mistake. To compensate for this error, Cytokinetics recently announced that they are increasing the size of their Phase II trial to 680 patients, which is good news for patients and researchers. The trial is expected to conclude in late 2013, and the results from the trial will be announced sometime in early 2014. Increasing the trial by 180 patients will cost an estimated additional $5 million. Read more about the changes to the Phase II trial by clicking the link below.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail